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Heparan sulfate proteoglycan in the glomerular basement membrane in
type 1 diabetes mellitus. Heparan sulfate proteoglycans (HSPG) are
negatively charged constituents of the renal extracellular matrix includ-
ing the glomerular basement membrane (GBM) and mesangial matrix.
Biochemical and functional studies of patients with type-l insulin
dependent diabetes meilitus (IDDM) suggest that alterations of HSPG
may occur in diabetic nephropathy. We have utilized a specific cy-
tochemical method and electron microscopy to quantitate the distribu-
tion of HSPG in the GBM of 10 normal people and in 16 IDDM patients
with a spectrum of clinical and structural changes. Enzyme incubation
studies of normal infant kidney demonstrated that heparitinase removed
94% of the stainable anionic sites in the lamina rara externa (LRE) and
77% of the sites in the lamina rara interna (LRI) of the GBM. In
contrast, incubation in the enzyme chondroitinase ABC did not reduce
the number of sites in the LRE but reduced the number of sites in the
LRI by 26%. The HSPG anionic sites in normal subjects were distrib-
uted in the LRE as 20.9 1.3, and in the LRI as 13.1 2.2 per micron
GBM length. Anionic sites were slightly reduced (19.6 1.3, P <0.04)
in the LRE of IDDM patients with normal urinary albumin excretion
rates (UAE), or microalbuniinuria, and were reduced in both the LRE
and LRI of IDDM patients with clinical proteinuria (13.1 2.3, P <
0.001 and 8.9 2.1, P <0.001, respectively). The number of anionic
sites in the LRE and LRI, respectively, correlated with UAE (r =
+0.78, P < 0.001, r = +0.58, P < 0.02), with GBM thickness (LRE, r
= +0.81, P < 0.001; LRI, r = +0.67, P < 0.01) and with the volume
fraction of mesangium (LRE, r = +0.59, P < 0.02; LRI, r = +0.58, P
<0.03). These data confirm earlier biochemical findings of a reduction
of HSPG in the GBM in advanced diabetic nephropathy but do not
provide evidence for the loss of HSPG in the GEM as a mechanism for
early microalbuminuria.
The glomerular capillary wall functions as a semipermeable
membrane which allows free permeation of water and small
molecules but excludes larger molecules to result in an ultrafil-
trate which is nearly protein free. The property of exclusion of
molecules of progressively larger sizes (size selectivity) has
been recognized for many years, and more recently an addi-
tional property of charge selectivity has been documented [11.
Negatively charged molecules, such as plasma albumin, are
restricted from the filtration in part due to their negative
charges. Thus abnormal permeability of the glomerular base-
ment membrane (GBM) to plasma proteins may be explained by
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alterations of the charge selective barrier or the size selective
barrier, or both.
The GEM consists of a filamentous network of collagen IV
and V fibrils, containing the large glycoproteins laminin and
nidogen, and anionic molecules of heparan sulfate proteogly-
can. Heparan sulfate proteoglycan molecules (HSPG) within
the GBM have been shown to have an important role in the
maintenance of the charge selective filtration barrier [2, 3],
since their removal by an in situ enzymatic digestion with
heparitinase leads to an increased permeability of the GBM to
ferritin [41 and 25I-labelled albumin [5]. These highly charged
molecules are also thought to be important in the maintenance
of the organization of the GBM constituents through their
chemical and electrostatic interactions with the other compo-
nents of the membrane [3, 6]. Most of these constituents are
known to self-assemble [6—10] and can bind to each other as
well as to other components of the GBM [3]. Tsilibary et al [6]
have shown that the electrostatic binding of heparin (which
resembles HSPG] to collagen IV inhibited the self-assembly of
collagen IV molecules, and have proposed that the qualititative
or quantitative alterations of HSPG molecules with the GBM,
which occur in pathological conditions such as diabetes melli-
tus, may alter the molecular assembly and function of basement
membranes.
In insulin-dependent diabetes mellitus (IDDM) increased
urinary excretion of albumin (UAE), undetectable by standard
tests (microalbuminuria), is considered by many investigators
to be an early marker in the clinical expression of the ongoing
development of the lesions of diabetic nephropathy, and to
predict the eventual development of clinically recognizable
proteinuria [11—15]. It has been proposed that UAE increases
gradually, ultimately leading to clinical proteinuria [15]. The
presence of clinically evident, "dip-stick" positive albuminuria
(>200 mg/24 hr) has a poor prognosis for survival of kidney
function over the subsequent ten years [16].
Biochemical studies of isolated GBM from IDDM patients
with "end-stage" diabetic nephropathy have demonstrated a
decreased content of HSPG, as compared to non-diabetic
kidneys [l7J. In addition several studies of experimental diabe-
tes in animals describe abnormalities of synthesis, sulfation,
content, and/or proteoglycan-matrix interaction of heparan
sulfate molecules in diabetic GBM [18—24].
Physiological studies of the fractional excretion of endoge-
nous plasma proteins [25, 26] and earlier studies of neutral
dextran molecules by diabetic patients [27] have also suggested
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Table 1. Clinical and anionic site data in ten normal human subjects
Patient
Age
years/sex LRE LRI
I
2
3
4
5
6
7
8
9
10
Mean SD
17/F
25/F
34/M
39/M
40/M
35/M
30/F
46/M
45/M
67/M
38 13.6
20.4 1.4
21.6 0.5
20.6 2.3
20.8 2.3
21.2 2.4
23.1 0.3
22.3 0.8
20.3 1.5
20.7 0.6
18.3 0.35
20.9 1.3
12.3 0.6
15.5 1.6
10.9 2.3
16.5 0.1
16.1 0.6
12.5 1.8
12.4 0.4
10.0 0.2
13.0 0.8
12.2 0.49
13.1 2.2
Abbreviations are: LRE, lamina rara externa, number of anionic sites
per 1000 nm glomerular basement (GBM) length (SD); and LR, lamina
rara interna, number of anionic sites per micron GBM length.
that the abnormal proteinuria of diabetic nephropathy may, in
part, be consequent to alterations of the anionic charge barrier
of the GBM. However, further studies by the latter group of
investigators have questioned these earlier observations and
concluded that a loss of the size selectivity barrier of the GBM,
associated with an increase in the number of larger, less
restrictive pores in the membrane, better describes the perme-
ability defect of IDDM [28].
We have utilized a cytochemical method for identification of
proteoglycans in tissue, developed by Scott [291, to label and
quantitate the anionic charge sites within the GBM of kidney
biopsy specimens from patients with IDDM and control sub-
jects. The commonly utilized cationic probes such as alcian
blue, ruthenium red, cationic ferritin, and polyethyleneamine,
involve electrostatic binding of the probe to the proteoglycan,
and their specificity is not high. The use of the critical electro-
lyte concentration method and cuprolinic blue increases the
specificity since only sulfate groups can bind the dye and only
sulfated proteoglycan molecules are stained [30, 31]. A prelim-
inary report of these studies in six diabetic patients has been
published [32].
Methods
Subjects
Morphologic studies were performed on kidney biopsy spec-
imens from 10 subjects without diabetes mellitus and clinical
and morphologic studies on 16 patients with IDDM.
Normal human kidney biopsy specimens were obtained from
ten subjects (3 female), ages 17 to 67 years. (38 13.6 years,
mean SD). Six were from donors for kidney transplantation
and four specimens were "normal" portions of kidney removed
for renal cell carcinoma. No differences between these subsets
of normals were found for any parameter studied and thus, the
results were combined. Relevant data for these control subjects
is presented in Table 1. All biopsy specimens were processed
within minutes of removal from the subjects. Stereologic stud-
ies were not performed on these normal specimens.
Diabetic subjects had kidney biopsies as a part of their
evaluation for possible pancreatic transplantation at our insti-
tution [33, 34]. The protocol for these studies was approved by
the Committee on Use of Human Subjects in Research at the
University of Minnesota. A total of 24 consecutive specimens
were prepared by the techniques described below, but four
contained inadequate material for this analysis, and four were
inadequately labelled. This judgment was based upon evalua-
tion of the adequacy of labelling of the anionic sites in the
interstitium of the kidney (anionic sites were labelled in the
interstitial collagen, tubular basement membranes, and intersti-
tial capillaries of all well-labelled specimens, but these struc-
tures are not discussed further in this study). The decision to
exclude poorly labelled specimens, and all morphologic analy-
ses, were made without knowledge of the clinical status of the
patients. The remaining 16 patients (12 female) are the study
group. Their ages ranged from 25 to 45 years (32 6.2 years)
with a duration of IDDM of 7 to 39 years (21 7.8 years) (Table
2).
Clinical studies in IDDM patients
Blood pressure was measured on at least ten occasions over
two to three days by experienced nurses during the patients'
stay on the Clinical Research Center (CRC).
Glomerular filtration rate was estimated by three 24-hour
creatinine clearances performed in the CRC under direct super-
vision, with the average value recorded, using laboratory
techniques as previously described [33, 34]. The average coef-
ficient of variation (CV) of separate specimens in the same
patient in this setting was 15%. The correlation of mean
creatinine clearances with inulin clearances in our hands in
IDDM patients whose GFR exceeded 45 ml/min/l .73 m2 is: r =
+0.92, P < 0.001 [34]. A creatinine clearance of 90 mllmin/
1.73 m2 was considered normal.
UAE was measured by the solid phase fluoroimmunoassay
method [35], utilizing three 24-hour urine specimens collected
as described above. The standard curve for this urinary albumin
assay was linear in the range of 500 to 2000 ng of albumin/mI
with a correlation coefficient of 0.99, The day to day CV of
these studies was 6.7%, which is in keeping with previous
studies using this method [34]. The mean 24-hour UAE rate
measured in 50 normal age-matched persons during evaluation
for kidney transplantation donation was 8.8 5 mg, with a
range of 1.3 to 20.5 mg [341.
The glycosylated hemoglobin (Hbg A1C), was measured on at
least two occasions by the Bio-Rad Hemoglobin A1C column
assay [36], with a normal range of 5.5 to 8.5%, and the averages
recorded. Relevant clinical data for the diabetic patients are
displayed in Table 2.
For analysis, patients were grouped on the basis of mean
24-hour urinary albumin excretion: Group Ia, normal UAE or
less than 20 mg!24 hrs (5 patients); Group Ib, microalbuminuria,
21 to 200 mg/24 hrs (3 patients); Group ha, early proteinuria,
>200 mg, <1 g/24 hrs (4 patients); and Group JIb, heavy
proteinuria, >1 g/24 hrs (4 patients).
Morphologic methods
Cytochemistry. This procedure has been described by Scott
[29], for localization of proteoglycans in tendon, and by van
Kuppevelt et al [30, 311 in mouse lung. One mm cubes of the
biopsy specimen were immersed in a freshly prepared basic
solution of 2% glutaraldehyde in a 0.2 M magnesium chloride
and in 0.025 M sodium acetate buffer (pH 5.6) containing 0.2%
cuprolinic blue (BDH Ltd., Poole, UK) for one hour (all at
room temperature). The blocks were then washed in the basic
1072 Vernier et a!: HSPG in type 1 diabetic nephropathy
Table 2. Demographic, clinical, anionic site, and morphometric data in 16 IDDM patients
Case no.
Age
years/sex
BP
mm
Hg
Ccr rn/I
min/1.73
m2
Hgb AIC
%
UAE mg124
hrs
Duration
of IDDM
years
LRE LRI v,
number of sites/micron (mes/glom) GBM
GBM length rnIm width nm
Group Iaa
I 32/M 118/74 134 7.3 7 26 19.5 13.9 0.17 494
2 26/F 102/66 109 7 7 7 20.3 13.4 0.17 368
3 43/F 104/62 108 7.2 9 39 21.6 13.5 0.23 410
4 34/F 99/66 70 8.3 5 30 17.9 10.3 0.30 503
5 32/F 114/70 ND 5.8 12 25 17.7 9.1 0.30 496
N 5 5 4 5 5 5 5 5 5 5
Mean 33 6.1 107/68 105 26 7.1 0.9 8 2.6 25 11.7 19.4 1.6 12.0 2.2 0.23 0.07 454 61
Group lb
6 32/F 103/63 71 11.4 35 29 20.5 11.7 0.22 420
7 31/F 114/72 105 7.4 62 23 19.9 14,9 0.30 310
8 31/F 110/68 85 9.2 45 16 19 11.7 0.18 772
N 3 3 3 3 3 3 3 3 3 3
Mean 31 0.6 100/67 87 17.1 9.3 2.0 47 13.7 23 6.5 19.8 0.8 12.8 1.8 0.23 0.06 501 241
Group I
N 8 8 7 8 8 8 8 8 8 8
Mean 33 4.8 108/68 97 23 8.0 1.7 23 21.7 24 9.6 19.6 1.3 12.3 2.0 0.23 0.06 472 139
Group ha
9 38/F 109/70 101 10.7 224 23 15.5 10.9 0.44 592
10 25/F 115/70 104 5.9 253 18 8.9 7.3 0.36 790
11 24/F 115/73 97 7.2 216 17 12.4 10.7 0.46 757
12 31/F 121/75 86 5.4 391 20 16 6.9 0.62 652
N 4 4 4 4 4 4 4 4 4 4
Mean 29 6.5 115/72 97 7.9 7.3 2.4 271 82 20 2.6 13.2 3.3 9.0 2.1 0.47 0.1 698 92
Group Hb
13 34/M 140/84 46 6.7 3163 19 12.5 12.1 0.42 689
14 25/M 120/78 70 7.9 1968 14 13.5 8.2 0.35 771
15 25/M 145/92 78 7.2 1942 12 14 8.7 0.28 650
16
N
45/F
4
146/81
4
46
4
7.3
4
3497
4
17
4
11.7 6.3 sclerosed gloms
4 4 3 3
Mean 32 9.5 138/84 60 16.5 7.3 0.5 2643 806 16 3.1 12.9 1.0 8.8 2.4 0.35 0.07 703 62
Group II
N 8 8 8 8 8 8 8 8 7 7
Mean 31 7.7 126/78 79 23 7.3 1.6 1457 1374 18 3.4 13.1 2,3 8.9 2.1 0.42 0.11 700 74
All diabetics
N 16 15 16 16 16 16 16 15 15
Mean 32 6.2 87 24 7.6 1.6 740 1196 21 7.8 16.3 3.3 10.6 2.6 0.32 0.13 578 161
BP, mean systolic diastolic blood pressure; Car, mean creatinine clearance; 11gb A1C, total glycosylated hemoglobin AIC component; UAE,
urinary albumin excretion; IDDM, insulin dependent diabetic mellitus; LRE, lamina rara externa of the glomerular basement membrane (GBM);
LRI, lamina rara interna of the GBM; V,, (mes/glom), fractional volume of the mesangium; ND, not done; scierosed gloms, scierosed glomeruli
in sample—not done.
a Group Ia = patients with normal UAE =<21 mg/daylb = patients with microalbuminuria = >21, <200 mg/dayha = patients with clinical proteinuria >200, <1 g UAE/dayJib = patients with heavy proteinuria = >1 g UAE/day
Data are mean standard deviation.
solution without the cuprolinic blue (x 2) and immersed in the
same solution containing 0.5% sodium tungstate for two hours.
Next, the samples were washed in the basic solution (><2) and
immersed in the same, containing 0.2% cuprolinic blue and
0.5% sodium sulfate for two hours. The tissue blocks were
washed in the basic solution, dehydrated in serial alcohol
solutions and embedded in Polybed®.
One micron thick sections were cut to identify glomeruli
available in the specimen. All non-scierosed glomeruli were thin
sectioned (60 nm) with diamond knives and prepared for
electron microscopy by staining briefly (5 mm) with uranyl
tcetate and lead citrate. After identifying the glomerulus within
the specimen, about 25 randomly spaced photographs of cross-
sectioned capillary walls were prepared and enlarged to about
50,000 magnifications. Magnification was assessed each day by
photographs of a replica grating standard. Photographs of
selected mesangial regions, tubular basement membranes, pen-
tubular capillaries, and interstitial matrix were also prepared for
each block examined. For the control specimens two to four
glomeruli (mean 2.5) were available, and for the diabetic
patients 46 total glomeruli were studied, which was a minimum
of 2 and a mean of 3.0 glomeruli per patient. All cytochemical
studies were completed by investigators who had no knowledge
of the clinical status of the patients.
The number of filamentous charge sites within the lamina
rarae of five or more capillaries per glomerulus were counted,
over a distance of about 100 cm (mean distance 109 cm) at
50,000 magnifications (actual mean length of capillary evaluated
per glomerulus = 21.4 ). in these preparations, the lamina rara
externa (LRE) was visible as a rather homogeneous, less dense
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linear zone of 50 to 70 nm width, limited by the epithelial cell
membrane and the dense lamina densa (LD). Filamentous
densities within this zone were enumerated as LRE anionic
sites. The lamina rara interna was less uniform in width, limited
by the endothelial cell membrane and the visible edge of the
LD. The width of the LRI varied between 85 and 125 nm in
normal subjects, but was more variable and often wider (up to
200 nm), in diabetic glomeruli. Nevertheless, all filamentous
densities within this zone were enumerated as LRI anionic
sites. Small, short, less dense filaments were noted within the
LD but were not quantitated.
Enzyme studies. To evaluate the effect of specific proteogly-
can degrading enzymes on the anionic sites in the GBM,
portions of kidney cortex from a normal newborn infant who
died of respiratory failure were obtained within one hour of
death. Small blocks (1 mm) were fixed in paraformaldehyde,
lysine, periodate (PLP) fixative, and freeze substituted in glyc-
erine, as previously described [37], frozen at —70°C, and stored
until used. These blocks were thawed in 2% glutaraldehyde in
0.025 M sodium acetate buffer at 4°C for one hour, washed in
buffer with protease inhibitors (below). A few blocks were
incubated in each of the following solutions:
1. Control: Routine cuprolinic blue technique as above,
except that the times of incubation were decreased to 30
minutes in solution I, one hour in solution II, and one hour
in solution III.
2. Heparitinase buffer: 0.1 N sodium acetate, 10 m calcium
acetate, with the protease inhibitors 5 mrvi benzamidine
HCL, and 0.1 M 6-amino-n caproic acid (Sigma Chemical
Co., St. Louis, Missouri, USA). Incubation was for two
hours at 43°C.
3. Chondroitinase buffer: 0.25 M Tris buffer [Tris (hydroxy-
methyl) aminomethane, Eastman Chemical Co., Roches-
ter, New York, USA], 0.18 M NaCl, with 0.05% bovine
serum albumin, and the same protease inhibitors as listed
in 2. Incubation was for 45 minutes at 37°C.
4. Chondroitinase ABC (ICN ImmunoBiologicals, Lisle, Ii-
linois, USA): 5 units/mI, in the buffer [3], as in 3.
5. Heparitinase (ICN ImunoBiologicals): 10 units/ml in the
buffer [2], as in 2.
All incubated blocks were then stained in cuprolinic blue
solutions as indicated for sample 1, washed, dehydrated, and
embedded in Polybed®. Ultra-thin sections were prepared from
at least two glomeruli per sample, randomly photographed, and
counted as described above.
Stereology. Electron microscopic morphometric analysis of
glomeruli from the diabetic subjects were performed using
glutaraldehyde fixed tissue and standard stereologic methods,
as previously described by this laboratory [33, 34, 38] and
others [39, 40]. The width of the GBM was estimated by the
orthogonal intercept method [41]. Normal GBM width in our
laboratory, based upon studies of 118 normal male and female
kidney transplant donors, was 349 49 nm [42].
The volume fraction of the mesangium per glomerulus
[Vv(mes/glom)] was determined by point counting [38], relating
the number of points falling on the mesangium and the number
of points falling on the reference area (the glomerula tuft;
normal mean SD for Vv(mes/glom) = 0.14 + 0.04) [421.
Table 3. Effects of specific enzymes and buffers on anionic sites in
the normal human GBM
Number of anionic sites pin
LRE LRI
1. Non-incubated (control) 27.3 2.2 22.5 1.1
2. Heparitinase buffer 24.2 3.5 17.4 0.2
3. Chrondroitinase buffer 29.7 3.5 23.0 0.8
Enzymes
4. Chondroitinase 24.7 1.9 17.2 04b
5. Heparitinase 1.4 0.8' 4.1 0.07"
° vs. 1 P < 0.024
b vs. 1 P <0.025, vs. 3 P < 0.013
vs. 1 P < 0.004, vs. 2 P < 0.012
d vs. I P < —0.002, vs. 2 P < 0.0005
Statistical methods
Statistical comparisons between the values for number of
anionic charge sites in normal subjects and each group of
diabetic subjects was determined by Student's t-tests. The
relationships between number of charge sites and other clinical
and morphometric data was assessed by simple linear regres-
sion. Calculations were performed on an Apple Mcintosh Plus
computer (Apple Computer Inc., Cupertino, California, USA)
using Statwork °" (Cricket Software, Philadelphia, Penn sylva-
nia, USA) and Microsoft Excel° (Microsoft Corporation,
Bellevue, Washington, USA). Values for P < 0.02 were con-
sidered significant, taking into account the number of analyses
performed.
Results
Enzyme incubation studies
The effects of incubation of fixed blocks of kidney cortex
from a normal infant in enzyme buffers with inhibitors and
specific proteoglycan degrading enzymes in these buffers, on
the subsequent staining of anionic sites in the GBM, is shown in
Table 3. The incubated samples are also compared with a
non-incubated sample, Note that the number of anionic sites in
the LRE in infants is increased as compared to older children
and adults, as shown in earlier studies using the polycationic
stain polyethyleneamine [43]. The number of anionic sites in the
LRE and LRI was reduced slightly, but not significantly, by
incubation in buffers alone, as compared to the non-incubated
specimen. Incubation in heparitinase reduced the number of
stained anionic sites in the LRE by 94% (P <0.002), and in the
LRI by 77% (P < 0.001), as compared to the buffers alone. In
contrast, incubation in the enzyme chondroitinase ABC did not
reduce the number of anionic sites in the LRE, but reduced the
number in the LRI by 26% (P < 0.013).
Normal kidney specimens
Densely stained short filaments representing anionic charge
sites were distributed in regular arrays within the LRE of the
normal GBM. Less regularly distributed but similar filaments
were present within the LRI (Fig. 1). The filaments appeared to
be arranged randomly within the lamina rarae; some were seen
in longitudinal section and others in cross or oblique section.
Occasional filaments within the LRE extended to or overlaid
the cell membrane of the epithelial cells. The mean number of
anionic sites in the LRE of 22 glomeruli from ten normal
'a
'Ii
GBM-LD
•' (se
LRI
m 'RI
m
a
P1
IL -
a
S %
I
J
1-
,t-.
LRE'.
ti—s — .;f,:., .. :-.:,
$ • 'I..: F' -w rt —. t
.
1074 Vernier et al: HSPG in type I diabetic nephropaihy
Fig. 1. Electron micro graph of portions of a glomerulus from a normal 34-year-old kidney donor stained with cuprolinic blue using the critical
electrolyte method, A. Stained filaments of heparan sulfate proteoglycan (HSPG) are regularly distributed within the lamina rara externa (LRE)
and, less frequently, within the lamina rara interna (LRI) of the glomerular basement membrane lamina densa (GBM-LD). Note also the numerous
filaments of HSPG distributed throughout the mesangial matrix (m) (18,800x). B. Detail of a peripheral segment of the GBM in this normal subject.
A few filaments are present within the lamjna densa (LD) of the GBM (47,000x). (Symbols are the same for Fig. 2.)
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kidneys was 20.9 1.3, per micron GBM length. In the LRI the
number of anionic sites per micron GBM length was more
variable, with a mean of 13.1 2.2. These data are displayed in
Table 1.
The anionic sites in the LRE of the GBM of diabetic
glomeruli differed from those in glomeruli of normal subjects in
that they appeared to be smaller (not quantitated; Fig. 2). An
increased number of small less densely stained sites was also
noted in the LD of diabetic subjects but these sites could not be
quantitated by current techniques and are not discussed further.
The mean number of anionic sites in the LRE of five patients in
Gp Ia with normal UAE and the three patients in Gp lb with
microalbuminuria were not different, and thus these data were
combined, resulting in a mean of 19.6 1.3, per micron GBM
length. This value approached but did not achieve statistical
significance when compared with the normal values in control
subjects (P < 0.04). The values for the number of anionic sites
in the LRE in Gp ha did not differ from those in Gp lib, and the
values were thus combined. The overall value for Gp II was
13.1 2.3. This value was significantly reduced as compared to
the control values (P < 0.001) and to Gp I (P < 0.001).
The anionic sites in the LRI of diabetic patients were more
variable in number, as described for the control subjects. The
number of sites per micron of GBM length in Gp Ia and Gp lb
combined was 12.3 1.9 (not significantly different from
normal), and in Gp ha and Gp JIb combined, 8.9 2.1. The
value for Gps Ila and JIb combined were significantly different
from the normal value (P < 0.001). The values for Gp II also
differed significantly from Gp I (P < 0.006).
In general the anionic sites in the LRE of the diabetic GBM
were smaller than those in control GBM, independent of the
extent of albuminuria; normal, microalbuminuria, clinical, and
heavy albuminuria.
The value for Vv(mes/glom) in Gp Ia was 0.23 0.07; Gp Ib,
0.23 0.06; Gp ha, 0.47 0.11; and Gp JIb, 0.35 0.07. The
thickness of the GBM in Gp Ia was 454 61 nm; Gp Ib, 501
241 nm; Gp ha 698 92 nm; and Gp JIb, 703 62 nm (Table
2).
There were significant correlations between the number of
anionic sites in the LRE and LRI of the GBM in diabetic
subjects and UAE [r = +0.78, P < 0.001 (Fig. 3A), and r =
+0.58, P < 0.018, respectivelyl, these correlations driven by
the patients with clinical proteinuria. The number of anionic
sites in the LRE and LRI and GBM thickness were also directly
correlated (r = +0.81, P < 0.001, and r = +0.67, P < 0.007,
respectively; Fig 3B). There were significant correlations be-
tween the number of anionic sites in LRE and (r = 0.59, P <
0.02) and the number of sites in the LRI and (r = 0.58, P <
0.023) and Vv(mes/glom) [Fig. 3d. There was no significant
correlation between the number of anionic sites in either the
LRE or LRI and creatinine clearance, duration of IDDM, or
HbA1C levels. Mean systolic and diastolic blood pressure in Gp
H was significantly higher than in Gp I (P < 0.007 and P <
0.005, respectively), due largely to the increased blood pressure
in patients in Gp lib.
Discussion
The critical electrolyte/polycationic dye cuprolinic blue
method, which allows accurate localization of proteoglycans in
various tissues [29—31, 44], was used to identify and enumerate
the anionic sites in the LRE and LRI of normal and diabetic
GBM, and to correlate a number of clinical and laboratory
variables with these values. The addition of the cationic dye to
a fixative (glutaraldehyde) reduces the loss of proteoglycans
during tissue processing to less than 1% [451.
The stainable sites in the GBM of a normal infant kidney were
largely removed by the enzyme heparitinase (94% reduction in
the number of sites in the LRE and 77% reduction in the LRI
sites, as compared to buffer controls). In contrast, chondroiti-
nase ABC did not reduce the number of stainable sites in the
LRE and reduced the number of sites in the LRI by 26%. Thus,
the method utilized primarily stains heparan sulfate PG sites in
the GBM. Similar, albeit qualitative, results have been reported
by Van Kuppefelt et al [31], in a study of anionic sites in the
mouse alveolar basement membrane. The present study sug-
gests that a minority of the anionic sites in the LRI of the human
GBM may consist of chondroitin sulfate PG.
We have shown that the stained PG filaments in the lamina
rarae of the normal GBM are regularly distributed with a
frequency of 20.9 1.29/micron in the LRE, and 13.1
2.19/micron, in the LRI. The pattern and distribution of the
filaments in the LRE of normal human kidney is similar to that
revealed by the cationic polymer polyethyleneamine (PEI) [43].
In that study it was shown, by selective and specific enzymatic
treatment of the sections, that the stained sites in the LRE were
primarily composed of heparan sulfate PG.
The present study indicates that the distribution of PG in the
LRE and LRI of diabetic patients with normal rates of UAE or
microalbuminuria (Gp I) were not significantly different from
the normal subjects, although a slight decrease in the number of
sites in the LRE was noted. In diabetic patients with clinical
albuminuria and heavy proteinuria (Gp II) a significant reduc-
tion in the number of PG sites in the LRE and LRI was
observed. An earlier study of the anionic sites in the GBM in
five patients with diabetic nephropathy, using PEI staining [46],
also described a decreased number of stained sites in the LRE
and LRI of diabetic GBM, but no quantitative data were
presented. Biochemical studies of isolated glomeruli from au-
topsy kidneys of diabetic patients with advanced nephropathy
have described a decreased content of glomerular HSPG as
compared to glomeruli from non-diabetic controls [17]. The
results of the present study are thus compatible with earlier
observations, suggesting a significant reduction of HSPG in the
GBM of diabetics with more advanced glomerular disease.
Since HSPG is known to be important in the self assembly and
organization of the matrix in many tissues [2, 3,6—101, including
the GBM and mesangial matrix, it is possible that the observed
decreased anionic sites in the GBM in more advanced diabetic
nephropathy and proteinuria could reflect disorganization of the
glomerular barrier function via alterations of glomerular pore
size, anionic charges, or both.
Shortly after onset of type 1 diabetes, functional alterations,
including increased GFR and renal plasma flow are detectable
[47], and the magnitude of these abnormalities is related to
glycemic control [48]. With time a subset of diabetic patients
develops persistent microalbuminuria [11], and at least four
groups of investigators have agreed that this represents "incip-
ient nephropathy" and indicates a high risk for ultimate pro-
gression to renal failure [11—15]. The basis of microalbuniinuria
and the mechanism whereby it could be a relatively early
Pig. 2. Baton snkrograpks of a po&on of a glomenslus from a 31-year-old patient with type I diabetes nsellltus 016yeast duration and
ndcroalbunth,nrla,stained with cuprolbsic blue and the critical electrolyte method. A. 11w OBM appears to be thickened (772 am by measurement)
and MsIa stained filaments atHSPG distributed prlnmrlly within the LRE and 111 in an apparently norami frequency. The nwnber ctHSPO. In the OBM-LD appears to be Increased. Note the numerous maawt at HSPO distributed 1d.srlly at the perlfleiy at the nStr
saint otmasaidil matrix (nO (l8800x). tDetail at the OBM In this patient. There Is an apparent Increased number otHSPG flwia&t within
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marker for the later development of advanced nephropathy are
not known. This study did not find a significant difference from
normal in the number of stained PG sites in the GBM of IDDM
patients with normal or microalbuminuria. However, since
small numbers of patients were studied, most with low level
microalbuminuria, no firm conclusion can be drawn from these
data.
It was initially shown that the sieving of neutral dextran
molecules by the GBM was normal in diabetic patients with
normal urinary albumin excretion rates, and with microalbumi-
nuria [27]. Nakamura and Myers [28], using similar glomerular
sieving techniques, concluded that a loss of barrier size selec-
tivity was the major defect underlying overt proteinuria in
diabetic nephropathy. More recently, this same group has
demonstrated an alteration in fractional dextran clearances in
IDDM patients with microalbuminuria, which is consistent with
both a size and charge selective defect in the glomerular barrier
[49].
Other physiological studies of the glomerular filtration barrier
in diabetes have produced controversial results, depending
upon the methods utilized. Kverneland et al [26] compared the
renal clearance of non-glycated and glycated albumin, which
differed slightly in charge, in 38 patients with IDDM, and
concluded that loss of anionic charge occurred in the early
stages of diabetic renal disease. Deckert et al [50] measured the
fractional clearances of four serum proteins which differed in
charge in 70 patients with IDDM, including 18 with microalbu-
minuria. These authors concluded that the increase in large
pore area seen in patients with clinical nephropathy was pre-
ceded by a loss of anionic sites in the GBM. Others have also
proposed that the deletion of anionic sites or their modification
by non-enzymatic glycation might account for the alteration of
the permeability of the filtration barrier and the proteinuria of
diabetes [18, 51—53].
The results of the present study do not fully answer the
question as to a role for deletion of proteoglycans from the
GBM as an early alteration in diabetes. The number of sites was
only minimally reduced in patients without overt proteinuria,
and this difference was of borderline statistical significance.
Further, there was no difference between normoalbuminuria
and microalbuminuria patients, although the sample size was
small. Finally, it should be noted that changes in the size of
charge sites could be visualized by electron microscopy as
changes in number, since smaller particles are less likely to be
included in the sections counted than larger ones [54]. Thus the
subtle decrease in LRE charge site density detected in IDDM
patients with normoalbuminuria or microalbuminuria, must be
viewed with caution.
An alternative hypothesis is that the proteinuria and the
changes in glomerular capillary wall HSPG in IDDM are the
consequence of advanced structural changes in the glomerulus
secondary to longstanding diabetes [33]. The outcome of
mesangial expansion and reduction in capillary filtration surface
[38] could trigger adaptive responses which resemble reduction
in renal mass [55, 56], resulting in an altered glomerular
capillary wall function with loss of size selectivity, and changes
in GBM HSPG, based upon glomerular hemodynamic and other
disturbances and consequent glomerular epithelial and endothe-
hal cell injury [57, 58). This hypothesis would be consistent with
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our observations of significant correlations between the reduc-
tion of HSPG anionic sites and albuminuria, and altered struc-
tural measures of GBM and mesangium in diabetic glomeruli.
The hypothesis has also been advanced that the hyperglyce-
mia accelerated formation of non-enzymatic glycation products
in diabetic tissue may contribute to the vascular complications
of diabetes mellitus [59—61], Thus, changes in permeability of
the blood vessels in diabetes could reflect permanent structural
alterations in GBM components such as collagen IV, secondary
to glycation. Further, the reduced quantity of HSPG in diabetic
GBM [17], and the reduced binding of anionic proteoglycans to
matrix proteins in diabetes [24, 621 may reflect the distortion of
important PG binding recognition sites in GBM via non-enzy-
matic glycation [611. Tarsio et al have described the non-
enzymatic glycation of fibronectin in experimental diabetes in
dogs [63], and fibronectin and collagen, in vivo and in vitro, and
showed a marked decreased binding of heparan to both glycated
fibronectin and collagen. Since several investigators have dem-
onstrated the interaction of multiple known components of the
GBM matrix, including fibronectin, collagen, and heparan sul-
fate proteogylcan (for which heparin is a model) [3, 6—101, it
seems possible that non-enzymatic glycation of any of these
components could result in perturbations of the assembly of the
GBM which might be reflected by increased permeability of the
GBM to macromolecules. However, our preliminary data show
no correlation between the extent of glycation of hemoglobin or
duration of diabetes and the number of anionic sites in the GBM
of diabetic patients. Thus, the wide range of duration of
exposure of glomerular proteins to the hyperglycemia of diabe-
tes (7 to 34 years) in patients in Gp I with normal or microal-
buminuria, and the wide range of diabetic glomerular lesions in
this group despite a uniform and normal number of anionic
sites, argues that glycation of GBM constituents acting through
a decrease in the number of HSPG anionic charge sites in the
GBM, is not a likely cause of the earlier aspects of alterations of
glomerular permeability in diabetic nephropathy.
In experimental diabetes in rats a decreased incorporation of
[35S] sulfate into GBM glycosaminoglycan [18—211, decreased
content of HSPG [2 1—23], and abnormalities of HSPG interac-
tion with other components of diabetic GBM have been de-
scribed [24]. Chakrabarti, Ma and Sima [641, showed decreased
stainable anionic sites in the GBM of diabetic BB rats as
compared to controls, using the methods described here. In
addition, a reduced level and decreased synthesis of a basement
membrane specific [65) extracellular matrix HSPG in Engel-
breth-Holm-Swarm tumors, implanted into diabetic mice, have
been reported [21, 22]. The HSPG isolated from the matrix of
the tumors grown in the diabetic mice was markedly reduced in
amount, but did not differ in size or in the charge of the
glycosaminoglycan side chains, as compared to normal control
tissue. These authors proposed that reduced HSPG concentra-
tions in the GBM might induce a compensatory increase in the
synthesis of other GBM components to correct for the in-
creased porosity which could be expected from the alteration of
the anionic charge barrier, as a consequence of reduced HSPG
synthesis. Deckert, Feldt-Rasmussen and Mathiesen [661 have
suggested that this hypothesis may be extended to provide a
mechanism for the increased accumulation of matrix compo-
nents in human diabetes.
Our data might be interpreted as being compatible with this
hypothesis, since we noted a highly significant correlation
between the number of anionic sites in both the LRE and LRI
and the thickness of the GBM in this small series of patients.
Similarly, there was a weaker, but significant correlation be-
tween the number of anionic sites in both the LRE and LRI and
the volume fraction of the mesangium. These observations, if
confirmed in larger numbers of diabetic subjects, may support
the concept advanced by Rohrbach et a! [21, 22] that a de-
creased synthesis, increased degradation, or failure of binding
of heparan sulfate proteoglycan within the diabetic GBM, may
be involved in the process of mesangial matrix accumulation
and GBM thickening, which are the fundamental pathological
lesions of diabetic nephropathy. However, the data in this
preliminary study indicate that a significant reduction of the
number of HSPG anionic sites in the diabetic GBM occurred
only when clinically important proteinuria and more advanced
morphologic manifestations of diabetic nephropathy were ob-
served. This may indicate that the loss of HSPG from the GBM
in diabetes is a secondary, rather than primary factor in the
development of the lesions. Until additional patients with a
wide range of clinical manifestations have been studied and the
anionic sites in the mesangium and other regions of the kidney
are evaluated longitudinally in normal and diabetic subjects, the
definitive role of HSPG in the pathogenesis of diabetic nephrop-
athy will remain unclear.
Acknowledgments
This work was supported by Grants from NIH (A1l0704, DK07087,
and AM13083), the Juvenile Diabetes Foundation, the Minnesota
Medical Foundation, and with the assistance of the Variety Club of the
Northwest. The authors appreciate the collaboration of Dr. David E. R.
Sutherland, Department of Surgery, University of Minnesota, who
made possible the study of both normal donor and diabetic kidney
specimens and Dr. Carl Smith, Department of Urology, Hennepin
County Medical Center, who made available normal portions of kidney
specimens from patients with renal cell carcinomas. We are indebted to
John Basgen and Thomas Groppoli for assistance with the quantitative
morphometry, Dr. Blanche Chavers and Ms. Sandy Spier for measure-
ment of urinary albumin, Marshall Hoff for photographic assistance,
Ms. Janice Sugden for statistical analysis, and Ms. Cynthia Dawis and
Ms. Sandy Cragg for secretarial support. The dedicated Nursing and
Diatetics staff of the Clinical Research Center makes such studies
possible.
Reprint requests to Robert L. Vernier M.D., Department of Pediat-
rics, University of Minnesota, Box 491 UMHC, 515 Delaware Street
S.E., Minneapolis, Minnesota 55455, USA.
References
1. BRENNER BM, HOSTETTER TH, HUMES HD: Molecular basis of
proteinuria of glomerular origin. N Engi J Med 298:826—833, 1978
2. FARQUHAR MG: The glomerular basement membrane: A selective
macromolecular filter, in Cell Biology of Extracellular Matrix,
edited by HAY ED, New York, London, Plenum Press, 1981, pp
335—378
3. TIMPLE R, DZIADEK M: Structure, development and molecular
pathology of basement membranes. In! Rev Exp Pathol 29:1—12,
1986
4. KANWAR YS, LINKER A, FARQUHAR MG: Increased permeability
of the glomerular basement membrane to ferritin after removal of
glycosaminoglycan (heparan sulfate) by enzymatic digestion. J Cell
Biol 93:486—494, 1982
Vernier er a!: HSPG in type I diabetic nephropathy 1079
5. ROSENZWEIG U, KANWAR YS: Removal of sulfated (heparan
sulfate) or non-sulfated (hyaluronic acid) glycosaminoglycans re-
sults in increased permeability of the glomerular basement mem-
brane to '251-bovine serum albumin. Lab Invest 34:177—184, 1982
6. TSILIBARY E, K0LIAK0s GG, CHARONIS AS, VOGEL AM, REGER
LA, FURCHT L: Heparin type IV collagen interactions: Equilibrium
binding and inhibition of type IV collagen self assembly. J Biol
Chem 362:19112—19118, 1988
7. YURCHENCO PD, FURTHMAYR H: Self-assembly of basement mem-
brane collagen. Biochemist,y 23:1839—1850, 1984
8. YURCHENCO PD, CHENG YS, RUBEN GC: Self-assembly of a high
molecular weight basement membrane heparan sulfate proteogly-
can into dimers and oligomers. J Biol Chem 262:17668—17676, 1987
9. YURCHENCO PD, TSILIBARY EC, CHARONIS AS, FURTHMAYR H:
Laminin polymerization in vitro. Evidence for a two-step assembly
with domain specificity. J Biol Chem 260:7636—7644, 1985
10. YURCHENCO PD, RUBEN GG: Basement membrane structure in
situ: Evidence for lateral associations in the type IV collagen
network. J Ce/I Biol 105:2559—2568, 1987
11. MOGENSEN CE: Urinary albumin excretion in early and long-term
juvenile diabetics. Scand J C/in Invest 28:101—109, 1971
12. VIBERTI GC, HILL RD. JARRETT RJ: Microalbuminuria as a pre-
dictor of clinical nephropathy in insulin-dependent diabetes melli-
tus. Lancet i:1430—1432, 1982
13. PARVING HH, OXENBOLL B, SVENDSEN PA: Early detection of
patients at risk of developing diabetic nephropathy: A longitudinal
study of urinary albumin excretion. Acta Endocrinol 100:550—555,
1982
14. MATHIESEN ER, OXENBOLL B, JOHANSEN K: Incipient nephrop-
athy in type I (insulin-dependent) diabetes. Diabeto/ogia 26:406—
410, 1984
15. MOGENSEN CE, CHRISTENSEN CK: Predicting diabetic nephrop-
athy in insulin-dependent patients. N Eng/ J Med 311:89—93, 1984
16. BORCH-JOHNSEN K, ANDERSEN PK, DECKERT T: The effect of
proteinuria on relative mortality in type I (insulin-dependent)
diabetes mellitus. Diabetologia 28:590—596, 1985
17. SHIROMURA H, SPIRO RG: Studies on macromolecular components
of human glomerular basement membrane and alterations in diabe-
tes. Diabetes 36:374—381, 1987
18. COHEN MP, SARMA MC: (355) sulfate incorporation into glomerular
basement membrane glycosaminoglycan is decreased in experimen-
tal diabetes. J Lab C/in Med 98:715—722, 1981
19. BROWN DM, KLEIN DJ, MICHAEL AF, OEGEMA TR: 35S-glycos-
aminoglycan and 35S-glycopeptide metabolism by diabetic glomer-
uli and aorta. Diabetes 31:418—425, 1982
20. KANWAR YS, ROSENZWEIG U, LINKER A: Decreased de novo
synthesis of glomerular proteoglycan in diabetes: Biochemical and
autoradiographic evidence. Proc Nat Acad Sci USA 80:2272—2275,
1983
21. ROHRBACH DH, WAGNER CW, STAR VU, MARTIN GR, BROWN
KS: Reduced synthesis of basement membrane heparan sulfate
proteoglycan in streptozotocin-induced diabetic mice. J Biol Chem
258:11672—11677, 1983
22. ROHRBACH DH, HASSELL JR. KLEINMAN HK, MARTIN GR: Alter-
ations in the basement membrane (heparan sulfate) proteoglycan in
diabetic mice. Diabetes 31:185—188, 1982
23. Wu VY, WILSON B, COHEN MP: Disturbances in glomerular
basement membrane glycosaminoglycans in experimental diabetes.
Diabetes 36:679—683, 1987
24. KLEIN D, OEGEMA TR, BROWN DM: Release of glomerular
heparan-35S04 proteoglycan by heparin from glomeruli of strepto-
zotocin-induced diabetic rats. Diabetes 38:1130—1139, 1989
25. VIBERTI 0, MACKINTOSH D, KEEN H: Determinants of the pene-
tration of proteins through the glomerular barrier in insulin-depen-
dent diabetes mellitus. Diabetes 32(Suppl 2):92—95, 1983
26. KvERNELAND H, FELDT-RASMUSSEN B, VID0L P, WELINDER B,
BENT-HANSEN L, SOEGAARD U, DECKERT T: Evidence of changes
in renal charge selectivity in patients with type I (insulin-depen-
dent) diabetes mellitus. Diabetologia 29:634—639, 1986
27. MYERS BD, WINETZ JA, CHuI F, MICHAELS AS: Mechanisms of
proteinuria in diabetic nephropathy: A study of glomerular barrier
function. Kidney mt 21:633—641, 1982
28. NAKAMURA Y, MYERS B: Charge selectivity of proteinuria in
diabetic glomerulopathy. Diabetes 37:1202—1211, 1988
29. SCOTT JE: Collagen-proteoglycan interactions. Localization of
proteoglycans in tendon by electron microscopy. Biochem J 187:
887—891, 1980
30. VAN KUPPEVELT THMSM, DOMEN JGW, CREMERS FPM, KUYPER
CMA: Staining of proteoglycans in mouse lung alveoli. I. Ultra-
structural localization of anionic sites. Histochem J 16:657—659,
1984
31. VAN KUPPEVELT THMSM, CREMERS FPM, DOMEN JGW, KUYPER
CMA: Staining of proteoglycans in mouse lung alveoli. II. Charac-
terization of the cuprolinic blue-positive, anionic sites. Histochem
J 16:671—686, 1984
32. VERNIER RU, SIssoN-Ross 5, MAUER SM: Cytochemical studies of
the anionic charges in the kidney in type I diabetes mellitus. Diab
Nephrop 5:15—18, 1986
33. MAUER SM, STEFFES MW, ELLIS EN, SUTHERLAND DER,
BROWN DM, G0ETZ FC: Structural-functional relationships in
diabetic nephropathy. J C/in Invest 74:1143—1155, 1984
34. CHAVERS BM, BILOUS RW, ELLIS EN, STEFFES MW, MAUER SM:
Urinary albumin excretion as a predictor of renal structure in type
I diabetic patients without overt proteinuria. N Eng! J Med 320:
966—970, 1989
35. CHAVERS BM, SIMONSON J, MICHAEL AF: A solid phase fluores-
cent immunoassay for the measurement of human urinary albumin.
Kidney ml 25:576—578, 1984
36. DAvis RE, NIc0L Di: A rapid simplified method for routine
measurement of glycosylated hemoglobin. Lancet ii:350—351, 1978
37. Ssso SP, VERNIER RU: Methods for immunoelectron micros-
copy: Localization of antigens in rat kidney. J Histochem Cy-
tochem 28:441—452, 1980
38. ELLIS EN, STEFFES MW, GOETZ FC, SUTHERLAND DER, MAUER
SM: Glomerular filtration surface in type I diabetes mellitus.
Kidney mt 29:889—894, 1986
39. Hntos K, OSTERBY R, NOZAWA M, GUNDERSEN HJG: Develop-
ment of glomerular lesions in long-term diabetes in the rat. Kidney
Int2l:689—695, 1982
40. OSTERBY R, PARVING HH, NYBERG 0, HOMMEL E, JORGENSEN
HE, LOKKEGARD H, SVALANDER C: A strong correlation between
glomerular filtration rate and filtration surface in diabetic nephrop-
athy. Diabetologia 31:265—270, 1988
41. JENSEN EB, GUNDERSEN HJG, OSTERBY R: Determinations of
membrane thickness distribution from orthogonal intercepts. J
Microsc (Oxford) 115:19—23, 1979
42. STEFFES MW, BARBOSA J, BASGEN JM, SUTHERLAND DER, NA-
.JARIAN iS, MAUER SM: Quantitative glomerular morphology of the
normal human kidney. Lab Invest 49:82—86, 1983
43. VERNIER RL, KLEIN Di, SissoN SP, MAHAN JD, OEGEMA TR,
BROWN DM: Heparan sulfate-rich anionic sites in the human
glomerular basement membrane. N Engi J Med 309:1001—1009,
1983
44. VAN KUPPEVELT THMSM, CREMERS FPF, DOMEN JGW, VAN
BENNIGEN HM, VAN DEN BRULE AJC, KUYPER CMA: Ultrastruc-
tural localization and characterization of proteoglycans in human
alveoli. Ear J Ce/I Biol 36:74—80, 1985
45. CHEN K, WIGHT TN: Proteoglycans in arterial smooth muscle cell
culture; an ultrastructural histochemical analysis. J Histochem
Cytochem 32:347—357, 1984
46. ROHRBACH R: Reduced content and abnormal distribution of an-
ionic sites (acid proteoglycans) in the diabetic glomerular basement
membrane. Virchows Arch B-Ce/I Pathol 5 1:127—135, 1986
47. MOGENSEN CE: Renal functional changes in diabetes. Diabetes
25:872—889, 1976
48. CHRISTIANSEN JS, GAMMELGAARD J, TONIER B, SVENDSEN PA,
PARVING HH: Kidney function and size in diabetics before and
during initial insulin treatment. Kidney Int 231:683—688, 1982
49. SCANDLING JD, MYERS BD: Glomerular size-selectivity and mi-
croalbuminuria in early diabetic glomerular disease. Kidney Int
41:840—846, 1992
50. DECKERT T, FELT-RASMUSSEN B, OJURUP R, DECKERT M: Gb-
merular size and charge selectivity in insulin dependent diabetes
mellitus. Kidney mt 33:100—106, 1988
51. SCHOBER E, POLLAK A. CORADELLO H, LUBEC 0: Glycosylation of
1080 Vernier et a!: HSPG in type 1 diabetic nephropathy
glomerular basement membrane components in type I (insulin-
dependent) diabetic children. Diabetologia 23:485—487, 1982
52. BROWNLEE M, VLASSARA H, CERAMI H: Nonenzymatic glycation
and the pathogenesis of diabetic complications. Ann mt Med
101:527—537, 1984
53. PARTHASARATHY N, SPIRO RG: Effect of diabetes on the glycos-
aminoglycan component of the human glomerular basement mem-
brane. Diabetes 31:738—741, 1982
54. GUNDERSEN HJG, BENOTSEN TR, K0RB0 L: Some new, simple
and efficient stereological methods and their use in pathological
research and diagnosis. APMIS 96:379—394, 1988
55. HOSTETrER TH, RENNKE HG, BRENNER BM: The case for intra-
renal hypertension in the initiation and progression of diabetic and
other glomerulopathies. Am J Med 72:375—380, 1982
56. HOSTETTER TH, OLSON JL, RENNKE HG, VENKATACHALAM MA,
BRENNER BM: Hyperfiltration in remnant nephrons: A potentially
adverse response to renal ablation. Am J Physiol 241 :F85—F93,
1981
57. OLSON JL, HOSTETTER TH, RENNKE HG, BRENNER BM, VENKA-
TACHALAM MA: Altered glomerular permselectivity and progres-
sive sclerosis following extreme ablation of renal mass. Kidney ml
22:112—126, 1982
58. YOSHIOKA T, SHIRAGA H, YOSHIDA Y, Fooo A, GLICK AD, DEEN
WM, HOYER JR, ICHIKAWA I: "Intact nephrons" as the primary
origin of proteinuria in chronic renal disease: Study in the rat model
of subtotal nephrectomy. J Clin Invest 82:1614—1623, 1988
59. VLASSARA H, BROWNLEE M, CERAMI A: Nonenzymatic glycation:
Role in the pathogenesis of diabetic complications. Gun Chem
32:37—42, 1986
60. GARLICK RL, BRUNN HF, SPIRo RG: Nonenzymatic glycation of
basement membranes from human gloméruli and bovine sources.
Diabetes 37:114.4—1150, 1988
61. BROWNLEE M, CERAMI A, VLASSARA H: Advanced glycosylation
end products in tissue and the basis of diabetic complications. N
Engi J Med 318:1315—1321, 1988
62. BROWNLEE M, VLASSARA H, CERAMI A: Aminoguanidine presents
hyperglycemia-induced defect in binding of heparin by matrix
molecules. (abstract) Diabetes 36(Suppl l):85A, 1987
63, TARSIO JF, WIGNESS B, RHODE TD, Ru WM, BUCHWALD H,
FURCHT U: Nonenzymatic glycation of fibronectin and alterations
of cell matrix and basement membrane components in diabetes
mellitus. Diabetes 34:477—484, 1985
64. CHAKRABARTI S, MA N, SIMA AAF: Reduced number of anionic
sites is associated with glomerular basement membrane thickening
in the diabetic BB rat. Diabetologia 32:826—828, 1989
65. HASSELL IR, ROBEY PG, BAWACH HH, WILCZEK J, RENNARD SI,
MARTIN GR: Isolation of a heparan sulfate-containing proteoglycan
from basement membrane. Proc Nati Acad Sci USA 77:4494—4498,
1980
66. DECKERT T, FELDT-RASMUSSEN B, MATHIESEN ER: Pathogenesis
of diabetic nephropathy: A hypothesis. Diab Nephrop 3:83—88, 1984
